Elcelyx was founded in 2010 to advance Gut Sensory Modulation (GSM) technology, based on the elucidation that enteroendocrine cells located in the lining of the lower gut can be modulated locally to elicit systemic physiological and pharmacological effects. This discovery affords a potentially safety-advantaged platform to develop novel therapies as well as re-position existing therapies to meet serious unmet needs.
http://www.Elcelyx.com
http://www.Elcelyx.com
Location: United States, California, San Diego
Employees: 11-50
Total raised: $64M
Founded date: 2009
Investors 2
| Date | Name | Website |
| - | Sailing Ca... | sailing-ca... |
| - | Lightstone... | lightstone... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 01.10.2015 | Series E | $40M | - |
| 14.02.2013 | Series C | $20M | - |
| 13.08.2012 | Series B | $4M | - |
Mentions in press and media 15
| Date | Title | Description |
| 01.10.2015 | Elcelyx raises $40M to push its reinvented diabetes drug to Phase III | Elcelyx Therapeutics, developing a long-acting formulation of the old diabetes treatment metformin, closed a $40 million funding round to advance its lead therapy toward pivotal trials. Metformin, introduced more than 50 years ago, is consi... |
| 01.10.2015 | Daily funding roundup - October 1, 2015 | General Assembly raised $70M; Neon Therapeutics secured $55M; Dolly landed $8M Social Finance (SoFi for short), a lending startup has raised a monster round of funding, taking $1 billion from SoftBank, with existing Third Point Ventures and... |
| 01.10.2015 | Elcelyx Therapeutics Gets $40M For Diabetes Treatment | San Diego-based Elcelyx Therapeutics, which is developing treatents for type 2 diabetes, said this morning that it has raised $40M in a Series E funding round. The funding came from new investor Sailing Capital, Clough Capital Partners, as ... |
| 01.10.2015 | Elcelyx Therapeutics Raises $40M in Series E Financing | Elcelyx Therapeutics, a San Diego, CA-based developer of pharmaceutical products for diabetes, raised $40m in Series E financing. The round was led by Sailing Capital, with participation from Clough Capital Partners, L.P., and existing inve... |
| 24.08.2015 | Elcelyx: Taking the GI, kidney distress out of diabetes drug metformin | Elcelyx has formulated a delayed release form of the the drug, which is meant keep diabetic blood sugars down without adding the stomach upset – and keeping the kidney functioning safely. It just released data from Phase 2 testing that it’s... |
| 14.02.2013 | Elcelyx Therapeutics Closes $20M Series C Financing Round | San Diego-based Elcelyx Therapeutics Inc. closed a $20 million Series C financing round to develop two diabetes-related products. The financing was led by San Diego’s GSM Fund LLC, a fund dedicated to this single investment. It is managed b... |
| 14.02.2013 | Elcelyx Therapeutics Completes $20M Series C | SAN DIEGO, CA, Elcelyx Therapeutics announced today the closing of a $20 million Series C financing to fund development of product candidates NewMet for Type 2 diabetes and Lovidia, an over-the-counter weight loss product. The financing w... |
| 14.02.2013 | Elcelyx Therapeutics Closes $20M Series C Financing | Elcelyx Therapeutics, a San Diego, CA-based developer of products for weight management and obesity-related metabolic disorders, closed a $20m Series C financing. The round was led by GSM Fund LLC, with participation from existing investors... |
| 13.08.2012 | Elcelyx Therapeutics Raises Additional $4M in Series B Funding | Elcelyx Therapeutics, a San Diego, CA-based developer of products for weight loss and the treatment of diabetes and obesity, has raised an additional $4m of a planned $7m extension of its Series B private equity funding. Backers include exi... |
| 13.08.2012 | Elcelyx Therapeutics Secures $4M | SAN DIEGO, CA, Elcelyx Therapeutics announced today that it has secured $4 million of a $7 million extension of its Series B private equity financing. >> Click here for more funding data on Elcelyx Therapeutics >> To export ... |
Show more